Castle Biosciences, Inc. – NASDAQ:CSTL

Add to watchlist

$19.9

-6.93

-25.83%

Market closed

Open in 1 day

+44.64%

month

+44.64%

quarter

+21.24%

year

Market Cap	764.59M
Enterprise value	484.98M

P/E	-8.76
EV/Sales	3.53
EV/EBITDA	-8.31
Price/Sales	4.33
Price/Book	1.48
PEG ratio	0.08
EPS	-1.14

Revenue	250.72M
EBITDA	-23.98M
Income	-30.79M
Revenue Q/Q	73.59%
Revenue Y/Y	64.70%

Profit margin	-48.99%
Oper. margin	-68.38%
Gross margin	76.64%
EBIT margin	-68.38%
EBITDA margin	-9.56%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Castle Biosciences Stock Forecast

M Q Y

Last Year

$39.5

Potential upside: 98.49%

Analysts Price target
Financials & Ratios estimates

Castle Biosciences, Inc. (NASDAQ:CSTL): Profit margin
Jun 2023	50.13M	-18.77M	-37.45%
Sep 2023	61.49M	-6.90M	-11.23%
Dec 2023	66.12M	-2.58M	-3.9%
Mar 2024	72.97M	-2.53M	-3.47%

Castle Biosciences, Inc. (NASDAQ:CSTL): Debt to assets
Jun 2023	425400000	46.63M	10.96%
Sep 2023	436019000	50.23M	11.52%
Dec 2023	477811000	86.54M	18.11%
Mar 2024	458507000	56.04M	12.22%

Castle Biosciences, Inc. (NASDAQ:CSTL): Cash Flow
Jun 2023	-3.78M	-15.38M	226K
Sep 2023	5.01M	-9.70M	45K
Dec 2023	24.07M	-7.67M	-3.29M
Mar 2024	-6.83M	-19.70M	10.64M

Castle Biosciences alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Castle Biosciences, Inc. (NASDAQ:CSTL): Employee count
Aug 2023	542
Sep 2023	582
Oct 2023	582
Nov 2023	582
Dec 2023	587
Jan 2024	587
Feb 2024	587
Mar 2024	610
Apr 2024	610
May 2024	610
Jun 2024	638
Jul 2024	638

Castle Biosciences
Hedge Funds Holdings Q1 2023

45.92% -38.34%

of CSTL is owned by hedge funds

91 -62

hedge funds hold CSTL stock

11.96M -10.20M

shares is hold by hedge funds

CSTL hedge funds holdings changes

Castle Biosciences
Insider Trading

Castle Biosciences, Inc. (NASDAQ:CSTL): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	23323
Feb 2024	0	23323
Mar 2024	0	38610
Apr 2024	0	34451
May 2024	0	26488
Jun 2024	0	5564
Jul 2024	0	2793
Aug 2024	0	6111
Sep 2024	0	23065
Oct 2024	0	15500
Nov 2024	0	29030
Dec 2024	0	46158

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	17 Dec 2024	MAETZOLD DEREK J director, officer..	Common Stock	9,252	$28.33	$262,137
Sale	17 Dec 2024	MAETZOLD DEREK J director, officer..	Common Stock	112	$28.76	$3,221
Sale	16 Dec 2024	MAETZOLD DEREK J director, officer..	Common Stock	11,059	$28.83	$318,864
Sale	13 Dec 2024	MAETZOLD DEREK J director, officer..	Common Stock	10,164	$28.47	$289,369
Sale	13 Dec 2024	MAETZOLD DEREK J director, officer..	Common Stock	3,321	$29.16	$96,840
Sale	13 Dec 2024	MAETZOLD DEREK J director, officer..	Common Stock	381	$28.47	$10,847
Sale	13 Dec 2024	MAETZOLD DEREK J director, officer..	Common Stock	124	$29.16	$3,616
Sale	13 Dec 2024	MAETZOLD DEREK J director, officer..	Common Stock	357	$28.47	$10,164
Sale	13 Dec 2024	MAETZOLD DEREK J director, officer..	Common Stock	117	$29.16	$3,412
Sale	13 Dec 2024	MAETZOLD DEREK J director, officer..	Common Stock	113	$28.47	$3,217

CSTL insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application METHODS OF DIAGNOSING AND TREATING PATIENTS WITH PIGMENTED SKIN LESIONS Filling date: 3 Aug 2021 Issue date: 3 Feb 2022	3 Aug 2021	3 Feb 2022
Application	Application METHODS OF DIAGNOSING AND TREATING PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA Filling date: 14 Aug 2020 Issue date: 5 Aug 2021	14 Aug 2020	5 Aug 2021
Application	Application METHODS OF DIAGNOSING AND TREATING PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA Filling date: 31 Jan 2020 Issue date: 5 Aug 2021	31 Jan 2020	5 Aug 2021
Application	Application DIAGNOSTIC TEST FOR PREDICTING METASTASIS AND RECURRENCE IN CUTANEOUS MELANOMA Filling date: 17 Jan 2020 Issue date: 19 Nov 2020	17 Jan 2020	19 Nov 2020
Application	Application METHODS FOR PREDICTING RISK OF RECURRENCE AND/OR METASTASIS IN SOFT TISSUE SARCOMA Filling date: 5 Jun 2017 Issue date: 22 Oct 2020	5 Jun 2017	22 Oct 2020

Castle Biosciences
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 2 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 28 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 3 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 2 Aug 2023	Q2 2023 Earnings Call Transcript

CSTL earnings call transcripts

Castle Biosciences
Executives

Insider	Age	Compensation
Mr. Derek J. Maetzold (1962) Founder, Chief Executive Officer, Pres & Director	63	$1,020,000
Mr. Frank Stokes (1970) Chief Financial Officer	55	$656,260
Mr. Bernhard E. Spiess (1960) Chief Bus. Officer	65	$528,350

Castle Biosciences
Latest News

Monday, 23 December 2024
08:50	Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term	zacks.com
07:00	Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test	businesswire.com
Thursday, 19 December 2024
07:00	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Tuesday, 17 December 2024
08:01	4 Solid Net Profit Margin Stocks to Boost Portfolio Returns	zacks.com
Monday, 16 December 2024
10:57	Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade	zacks.com
Thursday, 28 November 2024
08:50	Small Caps Are Winners of 2024: 5 Picks With Solid Short-Term Upside	zacks.com
Wednesday, 20 November 2024
07:00	Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference	businesswire.com
Friday, 8 November 2024
09:56	Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why	zacks.com
07:00	Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting	businesswire.com
Thursday, 7 November 2024
13:00	Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why	zacks.com
Monday, 4 November 2024
19:33	Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript	seekingalpha.com
18:56	Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates	zacks.com
Friday, 1 November 2024
10:16	Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue?	zacks.com
Tuesday, 29 October 2024
16:30	Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett's Esophagus Patients	businesswire.com
Monday, 28 October 2024
07:00	Castle Biosciences to Participate in Upcoming Investor Conferences	businesswire.com
Wednesday, 23 October 2024
09:51	Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going	zacks.com
Tuesday, 22 October 2024
13:06	Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy?	zacks.com
Sunday, 20 October 2024
05:00	Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors	businesswire.com
Wednesday, 16 October 2024
07:00	Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential	businesswire.com
Tuesday, 15 October 2024
10:22	Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out?	zacks.com
05:51	Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength?	zacks.com
Monday, 14 October 2024
07:00	Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024	businesswire.com
Friday, 11 October 2024
07:00	Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin	businesswire.com
Wednesday, 9 October 2024
07:00	New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences' DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions	businesswire.com
Monday, 7 October 2024
13:05	Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's What You Should Know	zacks.com
Wednesday, 2 October 2024
07:00	Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas	businesswire.com
Friday, 27 September 2024
17:15	New Data at ASTRO 2024 Shows Castle Biosciences' DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma	businesswire.com
Friday, 16 August 2024
06:41	Castle Biosciences: Inflection Into Profitability	seekingalpha.com
Monday, 5 August 2024
22:35	Castle Biosciences, Inc. (CSTL) Q2 2024 Earnings Call Transcript	seekingalpha.com
18:46	Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates	zacks.com

Ideas & Opinions

Seeking Alpha 15 Dec 2022

Castle Biosciences: Potential To Re-Rate With Supportive Fundamentals, Technicals, Underlying Market

Frequently Asked Questions (FAQ)

What's the price of Castle Biosciences stock today?

One share of Castle Biosciences stock can currently be purchased for approximately $19.9.
When is Castle Biosciences's next earnings date?

Unfortunately, Castle Biosciences's (CSTL) next earnings date is currently unknown.
Does Castle Biosciences pay dividends?

No, Castle Biosciences does not pay dividends.
How much money does Castle Biosciences make?

Castle Biosciences has a market capitalization of 764.59M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 60.38% to 219.79M US dollars.
What is Castle Biosciences's stock symbol?

Castle Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "CSTL".
What is Castle Biosciences's primary industry?

Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
How do i buy shares of Castle Biosciences?

Shares of Castle Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Castle Biosciences's key executives?
Castle Biosciences's management team includes the following people:
- Mr. Derek J. Maetzold Founder, Chief Executive Officer, Pres & Director(age: 63, pay: $1,020,000)
- Mr. Frank Stokes Chief Financial Officer(age: 55, pay: $656,260)
- Mr. Bernhard E. Spiess Chief Bus. Officer(age: 65, pay: $528,350)
Is Castle Biosciences founder-led company?

Yes, Castle Biosciences is a company led by its founder Mr. Derek J. Maetzold.
How many employees does Castle Biosciences have?

As Jul 2024, Castle Biosciences employs 638 workers, which is 5% more then previous quarter.
When Castle Biosciences went public?

Castle Biosciences, Inc. is publicly traded company for more then 6 years since IPO on 25 Jul 2019.
What is Castle Biosciences's official website?

The official website for Castle Biosciences is castlebiosciences.com.
Where are Castle Biosciences's headquarters?

Castle Biosciences is headquartered at 505 South Friendswood Drive, Friendswood, TX.
How can i contact Castle Biosciences?

Castle Biosciences's mailing address is 505 South Friendswood Drive, Friendswood, TX and company can be reached via phone at +86 67889007.
What is Castle Biosciences stock forecast & price target?

Based on 4 Wall Street analysts` predicted price targets for Castle Biosciences in the last 12 months, the avarage price target is $39.5. The average price target represents a 98.49% change from the last price of $19.9.

Castle Biosciences, Inc.

castlebiosciences.com

Exchange:

NASDAQ

Full time employees:

710

Industry:

Medical - Diagnostics & Research

Sector:

Healthcare

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

+86 67889007

505 South Friendswood Drive
Friendswood, TX 77546

CIK: 0001447362
ISIN: US14843C1053
CUSIP: 14843C105